The currently developed and validated in vitro tests for female and male fertility and also for developmental toxicity are described and evaluated according to their potential use as screening or replacement alternatives to the established in vivo tests in reproductive and developmental toxicology. Alternative methods today can only be used to evaluate a few specific components of the integrated reproductive functions in both females and males. However, in the field of developmental toxicity testing there is a strong theoretical and empirical basis for the predictive power of in vitro screens using mammalian embryos as well as embryonic cells and tissues. Several of these assays have been validated or are currently undergoing validation in several laboratories and are >80% concordant with in vivo results. Failure to achieve 100% accuracy reflects the inherent limitations of these systems, which are manageable, as the concordance rates are still good. The level of concordance suggests that these assays are adequate for screening purposes to complement traditional in vivo testing. The use of these assays as screens will save valuable in vivo testing resources for those compounds most likely to enter the market and to which people will be exposed. -Environ Health Perspect 106(Suppl 2):571-576 (1998). http.//ehpnet 1. niehs. nih.gov/docs/l 998/Suppl-2/571-576spielmann/abstract. html
Introduction
Reproduction is a continuous cycle. For the conducting mechanistic reproductive purposes of toxicity testing, however, it is toxicity studies. Additionally, in vitro methbroadly divided into pregnancy in females, ods already play a valuable role in so-called including prenatal or postnatal develop-secondary testing, i.e., in the screening of mental toxicity, and the remainder of the series of structurally related chemicals when cycle in both males and females during at least one of the chemicals is of known which fertility may be impaired.
reproductive toxicity in vivo. During the past 20 years research in The majority of research into the develreproductive toxicology has focused on opment of alternative tests has concentrated the use of alternatives to living mammals on teratogenicity, which is only one manifor testing the potential reproductive toxi-festation of adverse effects on development cities of chemical and physical agents. and does not cover fertility, which includes Recent reviews include an Organisation for sexual behavior, spermatogenesis, oogenesis, Economic Co-operation and Development fertilization and the development of the workshop in Ottawa, Canada, in 1992 (1) zygote up to term, postnatal development, and a European Centre for the Validation of and hormonal activity.
Alternative Methods (ECVAM) workshop InVivoTesting for in Ispra, Italy, in 1994 (2) . International IngVivo Purpor experts concluded at both conferences Regulatory Purposes that the use of in vitro methods is well Currently, reproduction/development established and that they are invaluable for screening tests (3, 4) 29 May 1997.studies must be conducted to provide information on the effects of industrial chemicals on all aspects of the highly complex reproductive cycle (5, 6) . For chemicals used as drugs, segment studies must be conducted covering three important phases of pre-and postnatal development and fertility (7) . Because of the complexity of the reproductive cycle, from gamete maturation through implantation of the early embryo into the uterus, and because of the lack of validated alternative tests for most steps in the cycle, testing in living animals is the only option currently available for assessing the possible effects of chemicals on reproduction. Moreover, because of the complexity of functions that are only found in living animals, in vitro screening may never be able to cover all of the aspects of fertility. Thus, the key question is whether sufficient information can be derived from alternative tests to be able to classify and label chemicals as toxic to the reproductive system.
Fertility: In Vitro Approaches
Female Fertility Some aspects of female reproductive function can be modeled in vitro, and several cellular components of the female reproductive organs can be maintained in culture (8) . Although none of the organs have been used or validated as toxicity screens, several may be useful for specialized toxicologic studies. In the future, a battery of such systems may be able to cover a large proportion of the female reproductive cycle.
In females, the proliferation of primordial germ cells and the initial steps of meiosis occur long before birth. From (14), mouse ovarian tumor (MOT) cells (15) , and neuroblastoma cells (16) . The results of a blind trial with a dual HEPM/MOT approach showed an unacceptably high level of false positives (> 50%) (17) . division, and differentiation all occur in micromass cultures (24) . In principle, the micromass test is based on detecting the ability of a particular chemical to inhibit the formation of foci. Embryonic limb or central nervous system (CNS) cells (usually midbrain, which form foci of neurons) from chick, mouse, or rat can be used (25, 26) . The technique has subsequently been modified for use with 96-well microtiter plates (27) . Cells can be exposed either directly in culture or transplacentally prior to culture (28) .
Several structure-activity studies have shown that the micromass test can distinguish between teratogens and nonteratogens within a particular chemical class, e.g., retinoids (28) and triazole antifungal drugs (29) . In some cases, organ-, species-, and strain-specific toxicity have been modeled in micromass cultures. For example, ethylenethiourea is more toxic to midbrain than to limb cultures (30) and is more toxic to the rat CNS than to the mouse CNS (31) .
Differentiating cells in both midbrain and limb cultures express cytochrome P450 isozymes (32) (26, 27, 33) . It is possible that much of this variation is accounted for by differences in the exact methodology used, and none of these studies are considered definitive.
Thus, micromass cultures represent robust test systems for studying potential teratogens. It was recommended that the micromass method be included in a comparative trial to determine its applicability relative to several other available in vitro systems (2 (34) . The overall accuracy in predicting teratogenic potential has been claimed to be 79 to 83% (34) . FETAX is low cost and rapid and uses a species commonly maintained under laboratory conditions. The assay is limited by the aqueous solubility of test substances, the relative lack of validation, and the small number of laboratories that have used the system. Nevertheless, it has been recommended that FETAX be induded in a comparative trial of alternative tests for developmental toxicity (1,2).
Avian Embryos
Although avian embryos are widely used as models in developmental biology, they have rarely been used for embryotoxicity testing. The chick embryotoxicity screening test (CHEST) was devised by Jelinek and co-workers (35) and has been used extensively in their laboratory, but not elsewhere. Intraamniotic injection eliminates the problem of continuous exposure of the embryo because the test substance is readily distributed to the extraembryonic compartments. Growth retardation, malformation, and death as well as dose-response and stage-response relationships and malformation spectra are easily determined. The results obtained from testing over 130 compounds have been published (35, 36) . One general problem with CHEST has been the inability to distinguish general toxicity from specific developmental effects.
Mammalian Whole Embryo Culture
Mammalian embryos can be maintained in culture for short periods throughout the phase from fertilization to the end of organogenesis (10) . For toxicity testing, the period from the end of gastrulation to midorganogenesis has been investigated extensively. Screening systems using mouse (37) and rat (38) embryos have been proposed, and the culture of rabbit embryos has recently been optimized (39 (41) have been used. The test compound can be added to the cultures for defined periods or for the entire culture period. Metabolic activation systems can be incorporated, including the addition of S9 or microsomal fractions of liver from different species, coculture with hepatocytes, sequential hepatocyte/whole embryo culture, and the addition of serum from treated animals or humans (42) .
At the end of the culture period a number of end points can be measured, including effects on the development of the visceral yolk sac vascularization and circulation; effects on hematopoiesis, embryonic growth (e.g., size and protein and DNA contents); and differentiation (number of somites, morphologic score); and dysmorphogenic effects (37, 38, 43 (43) and an interlaboratory validation study has been conducted (44) . In a validation study on different culture systems, six pairs of coded compounds were tested in chick and rat embryo cultures and in brain cell aggregate cultures (45 
Toxicokinetics and Metabolism
The production of a direct effect on the developing organism depends on the concentration/time relationship of the chemical and/or its active metabolite(s) in the target cells. Therefore, toxicokinetic and metabolism studies are of crucial importance for the design and interpretation of developmental toxicity studies with both in vitro and in vivo methods (47, 48) . In vivo target concentrations are dependent on maternal absorption of the compound, its distribution, metabolism, and excretion, and its placental transfer and distribution in the embryo. Toxicokinetic studies are also important in vitro. The presence of the compound and its stability in the culture medium must be verified, along with an assessment of its transport to, and uptake by, the tissues and cells in culture, its metabolic activation, and its cellular distribution. Toxicokinetic studies are essential for interpreting results obtained in vitro and for extrapolating these to the in vivo situation. Activities of added metabolizing systems, such as liver homogenate fractions, isolated enzymes, and hepatocytes, can be assessed by analytical techniques. Measurement of the compound in the cultured tissues and cells is critical, so the target concentration needed to yield an effect can be determined. Such measurements are especially important if little or no activity is observed in vitro so that false negatives can be excluded.
Toxicokinetic parameters often differ drastically between in vivo and in vitro situations. For example, in vivo drug levels can fluctuate markedly between doses because of the short half-lives of many chemicals, and high concentration peaks alternate with low or negligible drug levels. In contrast, the chemical is added in vitro to the culture medium and may persist for extended periods of time unless it is degraded by hydrolysis or enzymes present in the culture medium.
Discussion
The current status of in vitro tests for reproductive and developmental toxicity testing is summarized in Table 1 . It is obvious that for reproductive toxicity, alternative methods can only be used to evaluate a Eventually in vivo screening will only have to be conducted on compounds that passed the initial in vitro screen. In the latter two instances it may not be necessary to carry out any additional testing in vivo.
There are other applications of in vitro screens that should be considered seriously. The most significant potential application would be to set priorities for definitive testing of compounds that have been on the market for many years and for which no developmental toxicity data exist to date. Among these untested existing chemicals, in vitro screens would permit identifying compounds that may have developmental toxic potential. Using them will save time and money, but they will not replace in vivo testing for compounds to which people may substantially be exposed. They will, however, provide information on developmental toxicity for entire classes of compounds for which these data are never routinely obtained. Therefore, using validated in vitro tests will increase flexibility in product development and testing without compromising safety. In vivo tests will still be conducted on all new pharmaceutical agents and commercial chemicals for which exposure is significant. However, the in vitro tests will obviate the need to test in vivo materials when there is a high likelihood that their developmental toxicity potential would prevent their introduction into the market.
